EGFR and non-small cell lung carcinoma: Increasing evidence indicates that activation of somatic mutations in the EGFR kinase domain (exons 18–21) [1,2] confers sensitivity to the EGFR TKIs, such as gefitinib and erlotinib for patients with advanced NSCLC.